RLMD - NASDAQ

Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD·NASDAQ

$6.38

-0.62%
HealthcareBiotechnology

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$467.87M
EPS-1.4500
P/E Ratio-4.40
Earnings Date08/06/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. Earnings Call Transcripts

RLMD · NASDAQ

Related Guides

Blog Categories

Continue your RLMD research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.